75 results
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
business may be impaired.
S-17
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines … , including with respect to environmental, social and governance, or ESG, matters. A variety of organizations also measure the performance of companies
8-K
EX-1.1
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Entry into a Material Definitive Agreement
4:15pm
been denied any insurance coverage which it has sought or for which it has applied.
(y)Compliance with Environmental Laws. Except as could … , distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”); (ii) the Company
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
any such actions that may be brought against us, our business may be impaired.
S-17
If we fail to comply with environmental, health and safety laws … recently have been pursuing various rulemaking efforts, including with respect to environmental, social and governance, or ESG, matters. A variety
424B5
88z6430 3eemo5l6daj
23 Jun 22
Prospectus supplement for primary offering
4:09pm
8-K
EX-1.1
dtn4e8g mn2ab3ct
23 Jun 22
Other Events
4:04pm
424B5
6n5khb
22 Jun 22
Prospectus supplement for primary offering
4:05pm
424B5
v3efetkd4x72
1 Mar 22
Prospectus supplement for primary offering
5:12pm
8-K
EX-10.1
z9gybhaefhe
12 Jan 22
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
8:04am
8-K
EX-10.1
5oi ko1yq
1 Dec 21
Entry into a Material Definitive Agreement
4:02pm